Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Texas Health Dallas
InstitutionResearch output, impact & collaborations
Texas Health Dallas is a research organisation in Dallas, US. OpenAlex records 7,156 works and 558,184 citations for it. 1,768 researchers list it as their most recent affiliation.
7,156
Works
558,184
Citations
1,768
Researchers
63.3
Avg h-index
How has Texas Health Dallas's publication output changed over time?
ScholarIQpublication output · 2005–2021
Output grew0% over the shown period — from 1 works in 2005 to 1 in 2021.
1
1
1
4
2
1
1
1
20052006200720112012201320152021
Who are the most-cited researchers behind Texas Health Dallas?
ScholarIQtop researchers by citations
What are the most-cited papers on Texas Health Dallas?
ScholarIQmost cited works
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley Cohen, Karel Pavelká, Ronald van Vollenhoven, John T. Sharp, John L. Perez, G Spencer-Green
S132787887. 20051,788 Citations
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome
Roy Freeman, Wouter Wieling, Felicia B. Axelrod, David G. Benditt, Eduardo E. Benarroch, Italo Biaggioni, William P. Cheshire, Thomas Chelimsky, Pietro Cortelli, Christopher H. Gibbons, David S. Goldstein, R. Hainsworth, Max J. Hilz, Giris Jacob, Horacio Kaufmann, Jens Jordan, Lewis A. Lipsitz, Benjamin D. Levine, Phillip A. Low, Christopher J. Mathias, Satish R. Raj, David Robertson, Paola Sandroni, Irwin J. Schatz, Ron Schondorff, Julian M. Stewart, J. Gert van Dijk
Clinical Autonomic Research. 20111,686 Citations
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
S132787887. 20061,643 Citations
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome
Roy Freeman, Wouter Wieling, Felicia B. Axelrod, David G. Benditt, Eduardo E. Benarroch, Italo Biaggioni, William P. Cheshire, Thomas Chelimsky, Pietro Cortelli, Christopher H. Gibbons, David S. Goldstein, R. Hainsworth, Max J. Hilz, Giris Jacob, Horacio Kaufmann, Jens Jordan, Lewis A. Lipsitz, Benjamin D. Levine, Phillip A. Low, Christopher J. Mathias, Satish R. Raj, David Robertson, Paola Sandroni, Irwin J. Schatz, Ron Schondorf, Julian M. Stewart, J. Gert van Dijk
S74113319. 20111,241 Citations
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
New England Journal of Medicine. 2012944 CitationsOPEN ACCESS
How much of the research on Texas Health Dallas is open access?
ScholarIQopen access share
33%OPEN ACCESS
Gold
0%
Green
8%
Hybrid
0%
Bronze
25%
Closed
67%